Shandong Lukang Pharmaceutical Co Ltd (600789) - Total Assets
Based on the latest financial reports, Shandong Lukang Pharmaceutical Co Ltd (600789) holds total assets worth CN¥9.88 Billion CNY (≈ $1.45 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see cash efficiency ratio of Shandong Lukang Pharmaceutical Co Ltd for how efficiently the company converts equity into cash flow.
Shandong Lukang Pharmaceutical Co Ltd - Total Assets Trend (1993–2025)
This chart illustrates how Shandong Lukang Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See today's stock price for Shandong Lukang Pharmaceutical Co Ltd for real-time trading data and today's change.
Shandong Lukang Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Shandong Lukang Pharmaceutical Co Ltd's total assets of CN¥9.88 Billion consist of 49.3% current assets and 50.7% non-current assets. Explore working capital to net assets of Shandong Lukang Pharmaceutical Co Ltd to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 23.4% |
| Accounts Receivable | CN¥748.51 Million | 7.5% |
| Inventory | CN¥1.25 Billion | 12.4% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥910.41 Million | 9.1% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (1993–2025)
This chart illustrates how Shandong Lukang Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shandong Lukang Pharmaceutical Co Ltd's current assets represent 49.3% of total assets in 2025, an increase from 43.0% in 1993.
- Cash Position: Cash and equivalents constituted 23.4% of total assets in 2025, up from 0.0% in 1993.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 0.0% in 1993.
- Asset Diversification: The largest asset category is inventory at 12.4% of total assets.
Shandong Lukang Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Shandong Lukang Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
ASPEN PHAR.UN.ADR /1 O.N.
F:LDZU
|
Germany | €128.04 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Guizhou Bailing Group Pharmaceutical Co Ltd
SHE:002424
|
China | CN¥5.95 Billion |
|
Henan Taloph Pharmaceutical Stock Co Ltd
SHG:600222
|
China | CN¥3.68 Billion |
Shandong Lukang Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.53 | 1.28 | 0.96 |
| Quick Ratio | 1.14 | 0.86 | 0.53 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.68 Billion | CN¥909.76 Million | CN¥-108.19 Million |
Shandong Lukang Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Shandong Lukang Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.71 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | 10.3% |
| Total Assets | CN¥10.03 Billion |
| Market Capitalization | $1.27 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Shandong Lukang Pharmaceutical Co Ltd's assets below their book value (0.13x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Shandong Lukang Pharmaceutical Co Ltd's assets grew by 10.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Shandong Lukang Pharmaceutical Co Ltd (1993–2025)
The table below shows the annual total assets of Shandong Lukang Pharmaceutical Co Ltd from 1993 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥10.03 Billion ≈ $1.47 Billion |
+10.29% |
| 2024-12-31 | CN¥9.10 Billion ≈ $1.33 Billion |
+3.36% |
| 2023-12-31 | CN¥8.80 Billion ≈ $1.29 Billion |
+0.86% |
| 2022-12-31 | CN¥8.73 Billion ≈ $1.28 Billion |
+12.04% |
| 2021-12-31 | CN¥7.79 Billion ≈ $1.14 Billion |
+7.11% |
| 2020-12-31 | CN¥7.27 Billion ≈ $1.06 Billion |
+2.59% |
| 2019-12-31 | CN¥7.09 Billion ≈ $1.04 Billion |
+7.95% |
| 2018-12-31 | CN¥6.57 Billion ≈ $961.02 Million |
+26.25% |
| 2017-12-31 | CN¥5.20 Billion ≈ $761.20 Million |
+24.51% |
| 2016-12-31 | CN¥4.18 Billion ≈ $611.38 Million |
+3.98% |
| 2015-12-31 | CN¥4.02 Billion ≈ $588.00 Million |
-1.63% |
| 2014-12-31 | CN¥4.08 Billion ≈ $597.75 Million |
+0.25% |
| 2013-12-31 | CN¥4.07 Billion ≈ $596.27 Million |
+2.25% |
| 2012-12-31 | CN¥3.99 Billion ≈ $583.16 Million |
+14.47% |
| 2011-12-31 | CN¥3.48 Billion ≈ $509.42 Million |
+15.08% |
| 2010-12-31 | CN¥3.03 Billion ≈ $442.67 Million |
+22.06% |
| 2009-12-31 | CN¥2.48 Billion ≈ $362.67 Million |
-0.92% |
| 2008-12-31 | CN¥2.50 Billion ≈ $366.04 Million |
-0.30% |
| 2007-12-31 | CN¥2.51 Billion ≈ $367.15 Million |
+3.31% |
| 2006-12-31 | CN¥2.43 Billion ≈ $355.39 Million |
-6.06% |
| 2005-12-31 | CN¥2.59 Billion ≈ $378.32 Million |
-4.18% |
| 2004-12-31 | CN¥2.70 Billion ≈ $394.81 Million |
+0.06% |
| 2003-12-31 | CN¥2.70 Billion ≈ $394.59 Million |
+14.21% |
| 2002-12-31 | CN¥2.36 Billion ≈ $345.50 Million |
-0.79% |
| 2001-12-31 | CN¥2.38 Billion ≈ $348.25 Million |
+4.84% |
| 2000-12-31 | CN¥2.27 Billion ≈ $332.16 Million |
+26.68% |
| 1999-12-31 | CN¥1.79 Billion ≈ $262.20 Million |
+15.14% |
| 1998-12-31 | CN¥1.56 Billion ≈ $227.72 Million |
+17.20% |
| 1997-12-31 | CN¥1.33 Billion ≈ $194.30 Million |
+68.49% |
| 1996-12-31 | CN¥788.04 Million ≈ $115.32 Million |
+25.04% |
| 1995-12-31 | CN¥630.23 Million ≈ $92.22 Million |
+39.98% |
| 1994-12-31 | CN¥450.24 Million ≈ $65.88 Million |
+11.15% |
| 1993-12-31 | CN¥405.08 Million ≈ $59.28 Million |
-- |
About Shandong Lukang Pharmaceutical Co Ltd
Shandong Lukang Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in China. The company provides analgesics and antipyretics; gastrointestinal; endocrine; cardio-cerebrovascular; anti-infective; and other human formulation products. It offers human and veterinary active pharmaceutical ingredient; veterinary formulation; bio-pesticides; and amino acid. The company also exports its produ… Read more